( th LHRH analogs and antiandrogens 21 p...)Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference,Health

th LHRH analogs and antiandrogens, 21 patients (70%) had failed treatment with steroids and 15 patients (50%) had failed treatment with diethylstilboestrol. Moreover, all of the patients in the study had failed treatment with docetaxel and 10 patients (33%) had failed treatment with an additional cytotoxic agent (mitoxantrone, estramustine, vinorelbine, cyclophosphamide).

Of the 30 patients who have been treated, CB7630 was well tolerated with only minimal toxicity in this post-docetaxel population. In the 21 patients who have been in the study for over 3 months, 10 patients (48%) experienced a confirmed decline in PSA levels of greater than 50% and 2 patients (10%) experienced PSA declines of greater than 90%. Of the 12 evaluable patients with measurable tumor lesions, 2 patients (17%) experienced confirmed partial radiological responses (as measured by the RECIST criteria), 1 patient (8%) experienced an unconfirmed partial response and 5 patients experienced ongoing stable disease (including one patient with a minor response). Individual patients treated with CB7630 also experienced improvement in pain and a reduction in opioid use. Twenty-eight of the 43 patients (65%) enrolled in this trial are still receiving treatment with CB7630.

Dr. Arie S. Belldegrun, M.D., FACS, Vice Chairman of the Board of Directors of Cougar Biotechnology, said, "The data on CB7630 presented at the ESMO Conference is important for several reasons. First, not only does it confirm the earlier signal of clinical activity in second line hormonal therapy patients, but it also for the first time demonstrates that CB7630 is capable of impacting time to progression in patients with metastatic disease. The time to progression data presented in the CB7630 trial compares favorably to that which has been reported for other currently used second line hormonal therapies. Second, the data provides additional confirmation of CB7630's activity in second line chemotherapy patients. As both
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
3. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
7. Prana Biotechnology Presents New Key Findings on PBT2
8. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis